Skip to content

Connexin Genotypes in Cystic Fibrosis

Impact of Connexin 37, Connexin 43 on Clinical Disease Phenotype in Delta F508 Homozygous Patients With Cystic Fibrosis (CF) (CF-Modifier)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04242420
Enrollment
300
Registered
2020-01-27
Start date
2002-04-30
Completion date
2024-12-31
Last updated
2021-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Inflammation

Keywords

connexin 37+43, MBL, TGF beta, Lung function, Interleukin 8

Brief summary

Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508 homozygous patients. Gap junction proteins might be of importance for the influx of blood cells into the lung and may influence the course of pulmonary inflammation. A primary analysis (Horn et al. 2020) has shown that GJA4 variants (rs41266431) are linked to more severe disease in CF. This is very similar to variants of MBL. Aims: To assess the relationship between gap junction proteins alpha 1 (GJA1/Connexin 43) and alpha 4 (GJA4/connexin 37) genotypes and clinical disease phenotype. Moreover are GJA4 variants in terms of clinical phenotype independent of MBL variants. Methods:Patients homozygous for delta F508 get recruited from the CF centres of Bonn, Frankfurt and Amsterdam. Sequence analysis is performed for connexin 43 and 37 and MBL genotypes. Clinical disease is assessed longitudinally over 3 years by pulmonary function tests (FEV1 (forced expiratory volume in one second), FVC (=(forced vital capacity), FEF75 % (Forced expiratory flow at 75% of the pulmonary volume) pred), BMI (percentiles), P. aeruginosa colonization, diabetes mellitus and survival to end-stage CF lung disease (death or lung transplantation).

Detailed description

Progressive pulmonary destruction is the major cause of morbidity and mortality in human subjects with cystic fibrosis. Many studies could not find an association between delta F 508 and severity of pulmonary disease . The most important factor in CF lung disease is an inflammation driven by leukocytes and cytokines. The investigators have provided evidence in former studies that cytokines (Interleukin-8 (IL-8), tumour necrosis factor (TNF) alpha, Lipopolysaccahride binding protein (LBP), transforming growth factor (TGF) ß)measured in blood correlate negatively with lung function in delta 508 homozygous patients. The question arises, what other factors influence recruitment of proinflammatory leukocytes from blood capillaries into the lung . Connexins are a family of transmembrane proteins, which oligomerize into hexameric structures to form a hemichannel (connexon) and ultimately pair with a partner hemichannel in an adjacent cell to form gap junction intercellular communication channels (GJIC) . There is evidence of expression of connexin 37 (=gap junction protein A4 (GJA4)) on macrophages in humans. Moreover there is evidence of expression of connexin 37 on vascular endothelia in humans . Connexin 37 is expressed on human neutrophils . Pulmonary disease in CF is dominated by a leukocyte driven inflammation. GAP junction proteins might be of importance for the influx of blood cells into the lung. In this regard, the hypothesis was that Cx37 or Cx43 genotypes have an impact on clinical disease phenotype in CF patients homozygous for delta F508. The first analysis (Horn et al 2020) has shown a clinical phenotype linked to the GJA4 genotype is very similar to MBL variants. In this regard the question arises whether there is a link between the MBL variant alleles and the GJA4 variants. Moreover some TGFbeta genotypes are linked to certain pulmonary phenotypes. So we are looking for interactions between Cx37 and TGFbeta genotypes and their impact on the clinical phenotype as well.

Interventions

DIAGNOSTIC_TESTGenotyping

Genotyping for single nucleotide polymorphisms for Connexin 37&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes

DIAGNOSTIC_TESTLung function

Spirometry,

DIAGNOSTIC_TESTMicrobiology

Bacterial culture from Sputum or swab

DIAGNOSTIC_TESTBlood sample

Interleukin-8 assay (via chemiluminescence) blood cell count

DIAGNOSTIC_TESTInduced Sputum

Interleukin-8 assay (via chemiluminescence) blood cell count

Sponsors

Goethe University
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Evaluation of clinical parameters by genotype

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Homozygosity for delta F 508

Exclusion criteria

treatment with systemic steroids 14 days preceding this trial, participation in another study within the past 30 days, treatment with Orkambi or status after lung transplantation (for assessment of all parameters except survival).

Design outcomes

Primary

MeasureTime frameDescription
Lung function parameters: FEF753 yearsBest FEF75 value in % predicted of the year according to German registry according to Global lung initiative (GLI)
Lung function parameters: FVC3 yearsBest FVC value in % predicted of the year according to German registry according to Global lung initiative (GLI)
Survival to end stage lung diseasethrough study completion, on average 27 yearsEnd stage lung disease: Death or lung transplantation
Lung function parameter: FEV13 yearsBest FEV1 value in % predicted of the year according to German registry according to Global lung initiative (GLI)

Secondary

MeasureTime frameDescription
Inflammatory markers in sputumthrough study completion, an average of 3 yearLeukocyte count in sputum (single spot value (cross-sectional))
Interleukin-8 in bloodthrough study completion, an average of 3 yearsingle spot value (cross-sectional)
Interleukin-8 in sputumthrough study completion, an average of 3 yearsingle spot value (cross-sectional)
White blood cell countthrough study completion, an average of 3 yearLeukocytes (single spot value (cross-sectional))

Other

MeasureTime frameDescription
Colonisation with Pseudomonas aeruginosa3 yearsNever, Intermittent or chronic according to Leeds criteria
CF related diabetes mellitusthrough study completion, an average of 3 yearAssessment via patient charts/ registry

Countries

Germany, Netherlands

Contacts

Primary ContactSabina Schmitt-Grohe, MD
s.schmitt-grohe@ukbonn.de004915254568942

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026